Market Overview

Covidien to Acquire CV Ingenuity

Covidien
(NYSE: COV) announced a definitive agreement to acquire CV
Ingenuity. The companies expect to complete the acquisition
in the first calendar quarter of 2013. Financial terms of the
transaction were not disclosed.

CV Ingenuity, a privately-held company based in Fremont, CA, is focused
on improving patient outcomes in the treatment of peripheral arterial
disease (PAD) by providing solutions to relieve vascular obstructions,
inhibit restenosis, and allow natural vessel healing. The company's core
technology, while still in the investigational phase, is a Drug Coated
Balloon (DCB) platform with a novel, proprietary, tunable, rapid-release
system.

See full press release

Posted-In: News Guidance Contracts Management M&A Global

 

Related Articles (COV)

Around the Web, We're Loving...

Get Benzinga's Newsletters